Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02539511 · ClinicalTrials.gov registry record · Phase 2
Glutamatergic Modulation of Disordered Alcohol Use
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT02539511: Completed Phase 2 study, sponsored by New York State Psychiatric Institute.
NCT02539511 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02539511, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
Alcohol use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered drinking. Alcohol use disorders are recognized to be associated with various vulnerabilities that complicate the course of treatment and that may be amenable to glutamate modulators. The purpose of this randomized, double-blind, controlled trial is to test various glutamate modulators in conjunction with motivational enhancement therapy (MET) for alcohol use disorders.
Primary Outcome
Percentage of participants demonstrating alcohol abstinence in the control (midazolam) group versus the active (ketamine) group
Interventions
- DRUG CI-581a
- DRUG CI-581b
- BEHAVIORAL Motivational Enhancement Therapy (MET)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-07 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
What the finished NCT02539511 record still lists
NCT02539511 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 3 interventions - of which CI-581a is the first listed.
NCT02539511 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02539511 about?
NCT02539511 is a clinical study titled "Glutamatergic Modulation of Disordered Alcohol Use". Alcohol use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered drinking. Alcohol use disorders are recognized to be associated with various vulnerabilities that complicate the course...
What is the current status of trial NCT02539511?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2015-07. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02539511?
The interventions under investigation include: CI-581a (DRUG), CI-581b (DRUG), Motivational Enhancement Therapy (MET) (BEHAVIORAL).
Who is sponsoring clinical trial NCT02539511?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02539511's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia